Iecure Launches With $50 Million Series A Financing To Develop In Vivo Gene Insertion Approaches For Devastating Diseases
Sep 09, 2021•almost 4 years ago
Amount Raised
$50 Million
Round Type
series a
Description
iECURE (pronounced EE-ah-cure), a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, today announced it has closed a $50 million Series A financing led by Versant Ventures and OrbiMed Advisors. The funds will be used to advance iECURE’s pipeline of up to 13 programs, all of which benefit from gene editing and in vivo delivery approaches being developed in the laboratory of James Wilson, M.D., Ph.D., of the University of Pennsylvania Gene Therapy Program (GTP).
FundzWatch™ Score
88
Medium Activity
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech